Research analysts at HC Wainwright initiated coverage on shares of Proteon Therapeutics Inc. (NASDAQ:PRTO) in a note issued to investors on Thursday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research lowered shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 11th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $21.50.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics (NASDAQ:PRTO) opened at 8.75 on Thursday. Proteon Therapeutics has a 52 week low of $4.90 and a 52 week high of $17.76. The firm’s market cap is $145.09 million. The firm’s 50-day moving average is $9.10 and its 200-day moving average is $7.91.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/proteon-therapeutics-inc-prto-earns-buy-rating-from-analysts-at-hc-wainwright-2.html

Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, equities analysts anticipate that Proteon Therapeutics will post ($1.87) earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of PRTO. Geode Capital Management LLC increased its position in shares of Proteon Therapeutics by 6.3% in the first quarter. Geode Capital Management LLC now owns 45,412 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 2,685 shares in the last quarter. State Street Corp increased its position in shares of Proteon Therapeutics by 58.8% in the first quarter. State Street Corp now owns 94,432 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 34,952 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Proteon Therapeutics during the second quarter worth about $234,000. Deerfield Management Co. increased its position in shares of Proteon Therapeutics by 22.7% in the second quarter. Deerfield Management Co. now owns 1,552,031 shares of the biopharmaceutical company’s stock worth $12,463,000 after buying an additional 286,688 shares in the last quarter. Finally, Bridgeway Capital Management Inc. increased its position in shares of Proteon Therapeutics by 211.2% in the second quarter. Bridgeway Capital Management Inc. now owns 36,835 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 51.54% of the company’s stock.

About Proteon Therapeutics

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

5 Day Chart for NASDAQ:PRTO

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.